TreatER SIGNED
Clinical study in Parkinson's disease with two unique goals: 1) Proof-of-concept of CDNF protein for disease modification; 2) Validation of clinically tested device for intracerebral drug delivery
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0TreatER project word cloud
Explore the words cloud of the TreatER project. It provides you a very rough idea of what is the project "TreatER" about.
Project "TreatER" data sheet
The following table provides information about the project.
| Coordinator |
HELSINGIN YLIOPISTO
Organization address contact info |
| Coordinator Country | Finland [FI] |
| Project website | https://treater.eu/ |
| Total cost | 8˙705˙549 € |
| EC max contribution | 5˙971˙173 € (69%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SC1-2016-RTD |
| Funding Scheme | RIA |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-01-01 to 2020-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | HELSINGIN YLIOPISTO | FI (HELSINGIN YLIOPISTO) | coordinator | 597˙000.00 |
| 2 | REGION STOCKHOLM | SE (STOCKHOLM) | participant | 963˙125.00 |
| 3 | HERANTIS PHARMA OYJ | FI (ESPOO) | participant | 900˙000.00 |
| 4 | HELSINGIN JA UUDENMAAN SAIRAANHOITOPIIRIN KUNTAYHTYMÄ | FI (HELSINKI) | participant | 738˙125.00 |
| 5 | SKANE LANS LANDSTING | SE (KRISTIANSTAD) | participant | 716˙395.00 |
| 6 | RENISHAW PLC | UK (WOTTON UNDER EDGE) | participant | 700˙000.00 |
| 7 | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD | UK (OXFORD) | participant | 589˙028.00 |
| 8 | KAROLINSKA INSTITUTET | SE (STOCKHOLM) | participant | 525˙625.00 |
| 9 | ASSOCIATION EUROPEENNE POUR LA MALADIE DE PARKINSON | BE (BRUXELLES) | participant | 144˙375.00 |
| 10 | H. LUNDBECK AS | DK (VALBY) | participant | 48˙750.00 |
| 11 | ORION OYJ | FI (ESPOO) | participant | 48˙750.00 |
Map
Project objective
The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of intracerebrally administered CDNF protein therapy in patients with Parkinson’s disease (PD), using a neurosurgically implanted Drug Delivery System (DDS), which will also be clinically validated in the study.
Thus the TreatER project has two independent goals, either of which alone can have significant impact addressing unmet clinical needs in chronic diseases, and advancing innovative European technologies:
1) Proof-of-concept of CDNF protein therapy for disease modification in PD. The patented European innovation CDNF has further potential in other ER stress related indications.
2) Clinical validation of DDS, an already clinically tested approach for accurately targeted intracerebral infusions in PD. The patented European innovation DDS has also significant potential in other indications needing intracerebral infusions.
The clinical study builds on extensive preclinical research and related data on CDNF, including completed acute and chronic toxicology studies in non-human primates supporting an excellent safety profile. Further, the clinical study builds on existing clinical experience on DDS and related neurosurgery.
Both conventional and novel means for assessing the efficacy of the treatment will be utilized. This requires strong interdisciplinary expertise and knowledge available in the consortium, including: Regulatory expertise in drug and medical device development; neurological and neurosurgical expertise in PD; PET imaging expertise specific to PD; Scientific expertise in novel neurotrophic factors, in specific CDNF; and GMP manufacturing expertise of novel biological drug compounds.
Clinical trial applications are currently being submitted in Finland and Sweden, in accordance with previously obtained scientific advice from regulatory authorities in those countries as well as from MHRA (UK) and EMA's ITF.
Deliverables
| Midterm recruitment report, extension study | Documents, reports | 2020-03-25 16:14:59 |
| Midterm progress report WP4 | Documents, reports | 2020-03-25 16:14:59 |
| Midterm recruitment report | Documents, reports | 2020-03-25 16:14:59 |
| Patient information website | Websites, patent fillings, videos etc. | 2020-03-25 16:14:59 |
Take a look to the deliverables list in detail: detailed list of TreatER deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREATER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TREATER" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
PREFERABLE (2019)
Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life
Read MoreESCALON (2019)
European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development
Read MoreCLOSER (2019)
Childhood Leukemia: Overcoming distance between South America and Europe Regions
Read More